SCHEMBL2849416

SCHEMBL2849416

Nc1ccccc1C(=O)OC(=O)/C=C/c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.64
ALDH1A1 P00352 7/20 0.49
HSD17B10 Q99714 5/20 0.49
CFTR P13569 1/20 0.49
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 3/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
LMNA P02545 2/20 0.46
HDAC3 O15379 1/20 0.46
TNKS O95271 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2849418 1.00 MAPT (0.64) MAPTALDH1A1HSD17B10CFTRRAB9A
SCHEMBL21571614 0.90 MAPT (0.51) MAPTALDH1A1HSD17B10CFTRRAB9A
SCHEMBL11318439 0.89 GLA (0.55) MAPTALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL14801793 0.84 GUSB (0.52) MAPTALDH1A1HSD17B10RAB9ASMN1; SMN2
SCHEMBL23357451 0.84 ALDH1A1 (0.51) MAPTALDH1A1HSD17B10CFTRRAB9A
SCHEMBL28259523 0.83 ALDH1A1 (0.50) MAPTALDH1A1HSD17B10CFTRRAB9A
SCHEMBL14802090 0.82 MAPT (0.51) MAPTALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL8407382 0.81 MAPT (0.61) MAPTALDH1A1HSD17B10RAB9ASMN1; SMN2
SCHEMBL28839863 0.81 ALDH1A1 (0.56) MAPTALDH1A1HSD17B10CFTRRAB9A
SCHEMBL7557914 0.81 BCHE (0.53) MAPTALDH1A1HSD17B10CFTRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280441-B2 Host cells and methods for producing cinnamoyl anthranilate and analogs thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-07 US claimed
US-20140072584-A1 NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES LI, YINGJI (CN) 2014-03-13 US claimed
US-20130078683-A1 Host Cells and Methods for Producing Cinnamoyl Anthranilate and Analogs Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-03-28 US claimed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US claimed
CN-101600683-A Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2009-12-09 CN claimed
EP-2035369-A1 THERAPEUTIC COMPOUNDS Fibrotech Therapeutics PTY LTD (AU) 2009-03-18 EP claimed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO claimed
US-20230270703-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS OCCURX PTY LTD (AU) 2023-08-31 US disclosed
CN-116033901-A Compounds and methods for treating ocular disorders 奥克尔克斯有限公司 2023-04-28 CN disclosed
EP-4161527-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS OccuRx Pty Ltd (AU) 2023-04-12 EP disclosed
US-10280441-B2 Host cells and methods for producing cinnamoyl anthranilate and analogs thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-07 US disclosed
US-10280441-B2 Host cells and methods for producing cinnamoyl anthranilate and analogs thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-07 US disclosed
US-10280441-B2 Host cells and methods for producing cinnamoyl anthranilate and analogs thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-05-07 US disclosed
EP-2035369-A1 THERAPEUTIC COMPOUNDS Fibrotech Therapeutics PTY LTD (AU) 2009-03-18 EP disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed
CN-1713904-A Anthranilamides and derivatives thereof as cosmetically and pharmaceutically active compounds SYMRISE GMBH & CO KG (DE) 2005-12-28 CN disclosed
CN-1081623-C Benzene derivatives TEIJIN LTD (JP) 2002-03-27 CN disclosed
CN-1173169-A Benzene derivatives TEIJIN LTD (JP) 1998-02-11 CN disclosed
US-3998974-A Comestibles containing non-nutritive flavoring DYNAPOL CORPORATION (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072584-A1 NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES NFATC1, GABRA5, GABRA6 MAPT 4128/4885ALDH1A1 595/4885HSD17B10 753/4885
US-20230270703-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF EYE DISORDERS ALDH1A2, RBP4, RARB MAPT 3298/4885ALDH1A1 264/4885HSD17B10 1490/4885
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MAPT 3019/4885ALDH1A1 199/4885HSD17B10 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.